» Articles » PMID: 35547360

Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies

Abstract

Periodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host's immune response, which is characterized by increased expression of several inflammatory mediators such as cytokines and chemokines in the connective tissue. If periodontal disease (PD) is left untreated, it results in the destruction of the supporting tissues around the teeth, including periodontal ligament, cementum, and alveolar bone, which lead to a wide range of disabilities and poor quality of life, thus imposing significant burdens. This process depends on the differentiation and activity of osteoclasts, the cells responsible for reabsorbing the bone tissue. Therefore, the inhibition of differentiation or activity of these cells is a promising strategy for controlling bone resorption. Several pharmacological drugs that target osteoclasts and inflammatory cells with immunomodulatory and anti-inflammatory effects, such as bisphosphonates, anti-RANK-L antibody, strontium ranelate, cathepsin inhibitors, curcumin, flavonoids, specialized proresolving mediators, and probiotics, were already described to manage inflammatory bone resorption during experimental PD progression in preclinical studies. Meantime, a growing number of studies have described the beneficial effects of herbal products in inhibiting bone resorption in experimental PD. Therefore, this review summarizes the role of several pharmacological drugs used for PD prevention and treatment and highlights the targeted action of all those drugs with antiresorptive properties. In addition, our review provides a timely and critical appraisal for the scientific rationale use of the antiresorptive and immunomodulatory medications in preclinical studies, which will help to understand the basis for its clinical application.

Citing Articles

Exploring the Impact of Biological Agents on Protecting Against Experimental Periodontitis: A Systematic Review of Animal-Based Studies.

Oliveira G, Barbirato D, de Menezes B, Fuly M, Pelegrine H, Bonilha D Biomed Res Int. 2024; 2024:1716735.

PMID: 39654845 PMC: 11628168. DOI: 10.1155/bmri/1716735.


Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System.

Wang L, Zhang W, Zhao C, Fu Z Front Endocrinol (Lausanne). 2024; 15:1367607.

PMID: 39239094 PMC: 11374645. DOI: 10.3389/fendo.2024.1367607.


Variational Autoencoders for Generative Drug-Gene Interactions in Periodontal Bone Resorption.

Yadalam P, Ramadoss R, Anegundi R Cureus. 2024; 16(7):e65886.

PMID: 39219951 PMC: 11364490. DOI: 10.7759/cureus.65886.


The Efficacy of Topical or Systemic Antibiotics as Adjuvants to Non-Surgical Periodontal Treatment in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

de Molon R, Rodrigues J, Deroide M, Barbirato D, Garcia V, Theodoro L J Clin Med. 2024; 13(16).

PMID: 39200907 PMC: 11355856. DOI: 10.3390/jcm13164763.


Emerging therapeutic strategies targeting bone signaling pathways in periodontitis.

Valverde A, George A, Nares S, Naqvi A J Periodontal Res. 2024; 60(2):101-120.

PMID: 39044454 PMC: 11873684. DOI: 10.1111/jre.13326.


References
1.
Natto Z, Abu Ahmad R, Alsharif L, Alrowithi H, Alsini D, Salih H . Chronic Periodontitis Case Definitions and Confounders in Periodontal Research: A Systematic Assessment. Biomed Res Int. 2019; 2018:4578782. PMC: 6304204. DOI: 10.1155/2018/4578782. View

2.
Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

3.
Baron R, Ferrari S, Russell R . Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2010; 48(4):677-92. DOI: 10.1016/j.bone.2010.11.020. View

4.
Thompson S, Halbert S, Bossard M, Tomaszek T, Levy M, Zhao B . Design of potent and selective human cathepsin K inhibitors that span the active site. Proc Natl Acad Sci U S A. 1998; 94(26):14249-54. PMC: 24926. DOI: 10.1073/pnas.94.26.14249. View

5.
Akpinar A, Karakan N, Alpan A, Altintepe Dogan S, Goze F, Poyraz O . Comparative effects of riboflavin, nicotinamide and folic acid on alveolar bone loss: A morphometric and histopathologic study in rats. Srp Arh Celok Lek. 2018; 144(5-6):273-9. DOI: 10.2298/sarh1606273a. View